QR код

Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn’s Disease: A Prospective Cohort Study

<i>Background and Objectives</i>: Crohn’s Disease (CD) is a chronic inflammatory condition often treated with anti-TNF agents such as infliximab (IFX) and adalimumab (ADA). This study compares the efficacy, immunogenicity, and pharmacokinetics of IFX and ADA over a 54-week period. <i>Materials and M...

Повний опис

Збережено в:
Автори: Luis G. Guijarro, Patricia de Castro-Martínez, María Chaparro, Julio Acero-Sanz, Diego de León, Iván Guerra, Marisa Iborra, José Luis Cabriada, Luis Bujanda, Cristina Alba, Valle García-Sánchez, Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, Isabel Vera, María Dolores Martín-Arranz, Francisco Mesonero, Laura Sempere, Fernando Gomollón, Joaquín Hinojosa, Borja Hernández-Breijo, Melchor Alvarez-Mon, Javier P. Gisbert, Miguel A. Ortega
Формат: Artigo
Мова:Inglês
Опубліковано: MDPI AG 2025-12-01
Серія:Medicina
Предмети:
Crohn’s disease
infliximab
adalimumab
C-reactive protein
fibrinogen
immunogenicity
Онлайн доступ:https://www.mdpi.com/1648-9144/61/12/2165
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси